Transition of patients with mucopolysaccharidosis from paediatric to adult care
Christina Lampe(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Mireia del Toro(Universitat Autònoma de Barcelona), А. К. Геворкян(Scientific Center of Children's Health), Jordi Pérez‐López(Vall d'Hebron Hospital Universitari), Briony McNelly(Salford Royal NHS Foundation Trust), Christian J. Hendriksz(Birmingham Children's Hospital), Karolina M. Stępień(Salford Royal NHS Foundation Trust), Nato D. Vashakmadze(Scientific Center of Children's Health), Tinatin V. Lobzhanidze(Scientific Center of Children's Health)
Cited by 34
Related Papers
Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update
|Molecular Genetics and Metabolism|2012|478
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study
|Journal of Inherited Metabolic Disease|2014|211
Statin-induced myopathies
|Pharmacological Reports|2011|206